Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 43 clinical trials
Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC

The aim of this study is to compare time to progression between the combination pemetrexed-carboplatin and pemetrexed alone in previously treated patients with locally advanced or metastatic NSCLC.

  • 8 views
  • 07 Nov, 2020
  • 1 location
First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene

Current chemotherapy for advanced non-small cell lung cancer, not amenable for curative local treatment (surgery or chemoradiotherapy), has a modest life-prolonging effect and can improve quality of life. There is however no potential for long-term cure for these patients. Chemotherapy also produces variable and often significant toxicity. Current retrospective evidence …

measurable disease
serum bilirubin level
adenocarcinoma
chemoradiotherapy
platelet count
  • 27 views
  • 07 Nov, 2020
  • 1 location
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

, Vinorelbine, Ixabepilone, or the control arm (non-microtubule targeted chemotherapies such as doxorubicin, carboplatin, or gemcitabine).

breast cancer
doxorubicin
paclitaxel
cancer chemotherapy
carboplatin
  • 8 views
  • 29 Jan, 2021
  • 1 location